ALK and neuroblastoma: Through the implementation of precision oncology and the use of high-throughput sequencing within the Italian protocol of personalized medicine (PREME) for NB [12], we explored the possibility of applying precision medicine to the management of refractory/relapsed NB patients by discovering actionable ALK alterations.